The estimated Net Worth of Santo J Costa is at least $1.55 Milione dollars as of 1 September 2022. Mr. Costa owns over 15,000 units of Cytokinetics Inc stock worth over $1,344,250 and over the last 14 years he sold CYTK stock worth over $0. In addition, he makes $207,206 as Independent Director at Cytokinetics Inc.
Sign up
Mr. Costa CYTK stock SEC Form 4 insiders trading
Santo has made over 8 trades of the Cytokinetics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of CYTK stock worth $154,050 on 1 September 2022.
The largest trade he's ever made was exercising 29,999 units of Cytokinetics Inc stock on 11 May 2020 worth over $254,692. On average, Santo trades about 3,495 units every 59 days since 2010. As of 1 September 2022 he still owns at least 25,000 units of Cytokinetics Inc stock.
You can see the complete history of Mr. Costa stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Santo Costa biography
Santo Joseph Costa is Independent Director of the Company. Mr. Costa has served as a member of our Board of Directors since November 2010. Since 2007, Mr. Costa has served as Of Counsel to the law firm of Smith, Anderson, Blount, Dorsett, Mitchell and Jernigan, L.L.P. of Raleigh, North Carolina, specializing in corporate law for healthcare companies. From 1994 to 2001, he held various positions at Quintiles Transnational Corporation, including as Vice Chairman, President and Chief Operating Officer. Prior to joining Quintiles, Mr. Costa spent 23 years in the pharmaceutical industry, most recently as General Counsel and Senior Vice President, Administration with Glaxo Inc. Prior to joining Glaxo, he served as U.S. Area Counsel with Merrell Dow Pharmaceuticals, Inc. and as Food & Drug Counsel with Norwich Eaton Pharmaceuticals, Inc. Mr. Costa has served as Chairman of the Board of Directors of Alchemia Limited, a biopharmaceutical company, from March 2014 to June 2015. He served on the Board of Directors of Magor Corporation, formerly Biovest Corp. I, from March 2010 until March 2013. He served on the Board of Directors of Metabolon, Inc., a private company, from April 2013 to May 2019, serving as Chairman of the Board of Directors from February 2015 to May 2019. He served as Chairman of the Board of Directors of LaboPharm, Inc. from 2006 to 2011 and a director of OSI Pharmaceuticals from 2006 to 2010. He serves as Chairman of the Board of Directors of Aquestive Therapeutics, Inc. since August 2018 and as a member of the company’s Board of Directors since December 2015, as well as serving as a director at other private companies. Mr. Costa earned both a B.S. in Pharmacy and a J.D. from St. John’s University.
What is the salary of Santo Costa?
As the Independent Director of Cytokinetics Inc, the total compensation of Santo Costa at Cytokinetics Inc is $207,206. There are 14 executives at Cytokinetics Inc getting paid more, with Robert Blum having the highest compensation of $3,475,980.
What's Santo Costa's mailing address?
Santo's mailing address filed with the SEC is 280, East Grand Avenue, South San Francisco, San Mateo County, California, 94080, United States.
Insiders trading at Cytokinetics Inc
Over the last 21 years, insiders at Cytokinetics Inc have traded over $50,353,277 worth of Cytokinetics Inc stock and bought 879,922 units worth $7,454,506 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Capital Ltd Portfolio Servi... e Partners L P/Ilbiotechnolog.... On average, Cytokinetics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,225,580. The most recent stock trade was executed by B Lynne Parshall on 9 September 2024, trading 5,000 units of CYTK stock currently worth $108,050.
What does Cytokinetics Inc do?
cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.
What does Cytokinetics Inc's logo look like?
Complete history of Mr. Costa stock trades at Cytokinetics Inc e Aquestive Therapeutics Inc
Cytokinetics Inc executives and stock owners
Cytokinetics Inc executives and other stock owners filed with the SEC include:
-
Robert Blum,
President, Chief Executive Officer, Director -
Fady Malik,
Executive Vice President - Research and Development -
Mark Schlossberg,
Senior Vice President, General Counsel, Secretary -
Ching Jaw,
Chief Financial Officer, Senior Vice President -
David Cragg,
Chief Human Resource Officer, Chief Administrative Officer -
Robert I. Blum,
CEO, Pres & Director -
Dr. Fady Ibraham Malik,
Exec. VP of R&D -
Mark A. Schlossberg,
Sr. VP of Legal, Gen. Counsel & Sec. -
Ching W. Jaw,
Sr. VP & CFO -
David W. Cragg,
Chief HR & Admin. Officer -
Leonard Patrick Gage,
Independent Chairman of the Board -
Wendall Wierenga,
Independent Director -
B. Lynne Parshall,
Independent Director -
John Henderson,
Independent Director -
Santo Costa,
Independent Director -
Sandford Smith,
Independent Director -
Edward Kaye,
Independent Director -
Robert Califf,
Independent Director -
Nancy Wysenski,
Independent Director -
Diane Weiser,
IR Contact Officer -
Robert Wong,
Chief Accounting Officer, Vice President -
Kari K. Loeser J.D.,
VP & Chief Compliance Officer -
Robert Wong,
VP & Chief Accounting Officer -
Jeff Lotz,
VP of Sales & Operations -
Dr. James A. Spudich Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Bradley Paul Morgan,
SVP Drug Discovery & Early Dev -
Caryn Gordon Mc Dowell,
GC & Chief Compliance Officer -
Elisabeth Schnieders,
Sr. VP, Business Development -
L Patrick Gage,
Director -
Bonnie Charpentier,
SVP Regulatory & Compliance -
Robert Arthur Harrington,
Director -
Associates Vi Lp Srb,
10% owner -
Sung Lee,
EVP, Chief Financial Officer -
Peter S Roddy,
SVP Finance & CAO -
Muna Bhanji,
Director -
Michael Rabson,
SVP Business Dev/Legal & GC -
A Grant Iii Heidrich,
Director -
Mark Mcdade,
Director -
Brett A Pletcher,
EVP, Chief Legal Officer -
Sharon Barbari,
Sr. VP, Finance & CFO -
Charles J Homcy,
Director -
James H Sabry,
President and CEO -
David J Jr Morgans,
SVP-Drug Discovery and Dev -
James A Spudich,
Director -
Michael Schmertzler,
Director -
Jay K Trautman,
VP, Technology -
Stephen M Dow,
Director -
Denise Gilbert,
Director -
Capital Ltd Portfolio Servi...,
-
Suisse First Boston/Credit ...,
-
John Vdomenik Stephen Lbayl...,
-
William J Rutter,
Director -
Ixmayfield Ix Management Ll...,
-
Rosen Vii Affiliates Fund L...,
10% owner -
Associates Vii Lp Srb,
10% owner -
Associates Viii Lp Srb,
10% owner -
Rosen Viii Affiliates Fund ...,
10% owner -
Rosen Fund Viii Lp Sevin,
10% owner -
Rosen Fund Vi Lp Sevin,
10% owner -
Rosen Fund Vii Lp Sevin,
10% owner -
Rosen Vi Affiliates Fund Lp...,
10% owner -
Partners L P/Ilbiotechnolog...,
-
Partners L P/Ilbiotechnolog...,
-
Andrew Callos,
EVP, Chief Commercial Officer